Medical/Pharmaceuticals

Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy

MELBOURNE, Australia and SAN FRANCISCO, June 23, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the Italian Medicin...

2022-06-23 23:00 3209

I-Mab Receives Top Rankings in Five Categories by Institutional Investor

GAITHERSBURG, Md. and SHANGHAI, June 23, 2022 /PRNewswire/ -- I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it was ranked among the top companies i...

2022-06-23 20:00 2281

China Pharma Announces Receipt of Noncompliance Notice from NYSE American

HAIKOU, China, June 22, 2022 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that onJune 15, 2022, the Company received a letter from NYSE American LLC ("NYSE American" or the "Exchange"...

2022-06-23 05:00 3553

Prof. Cho, head of the lung cancer center at Yonsei Cancer Hospital, "J INTS BIO's new oral administration 4th generation EGFR TKI 'JIN-A02' expected to be a game changer"

SEOUL, South Korea, June 21, 2022 /PRNewswire/ -- Prof. Cho Byoung-chul at Yonsei University College of Medicine (Director, Lung Cancer Center, Yonsei Cancer Hospital) is one of the most influential researchers in the lung cancer field and is involved in the development of innovative new drugs gl...

2022-06-21 17:00 1963

Nippon Express Launches New Transport Service Using Environment-friendly Isothermal Packaging

TOKYO, June 21, 2022 /PRNewswire/ -- -First Japanese Logistics Company to Collaborate with EMBALL'ISO, Experienced in Vaccine Transport- Nippon Express Co., Ltd., a group company of Nippon Express Holdings, Inc., has become the first Japanese logistics company to collaborate with EMBALL'ISO, a...

2022-06-21 14:00 1667

Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's Lymphoma

ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodia's unique antibody-cell conjugation (ACC) technology as an optimized T cell engager platform to treat patients with non-Hodgkin's lymphoma ALAMEDA, Calif. and TAIPEI, Taiwan, June 20, 2022 /PRNews...

2022-06-20 20:00 2463

2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines

TAIPEI, Taiwan , June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winne...

2022-06-19 10:30 3815

2022 Tang Prize in Biopharmaceutical Science Honors Three Scientists for Developing COVID-19 mRNA Vaccines

TAIPEI, Taiwan, June 18, 2022 /PRNewswire/ -- After the 2014 and 2016 winners for the Tang Prize in Biopharmaceutical Sciences were crowned the Nobel Prize in 2018 and 2020 respectively, this category has continued to garner much attention worldwide. After much waiting, names of the latest winner...

2022-06-19 10:30 3820

Memorial MRI & Diagnostic Installs United Imaging's Pioneering 75 cm, Ultra-Wide-Bore uMR OMEGA™

HOUSTON, June 17, 2022 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment, and Memorial MRI & Diagnostic, a leader in diagnostic and imaging services inTexas, celebrated the installation of new technology for its patients inKaty, T...

2022-06-17 21:00 5067

US FDA AWARDS ORPHAN DRUG DESIGNATION (ODD) TO PAXALISIB FOR AT/RT, A RARE FORM OF CHILDHOOD BRAIN CANCER

SYDNEY, June 17, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that the United States Food and Drug Administration (FDA) has awarded Orphan Drug Designation (ODD) to Kazia's paxalisib for the treatmen...

2022-06-17 20:00 5057

Bon Natural Life Limited Introduces New Powder Drink For Anti-H. Pylori and Digestive Health

XI'AN, China, June 16, 2022 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced that it has launched a new cruciferous vegetable based probiotic ...

2022-06-16 20:30 4922

111, Inc. Announces First Quarter 2022 Unaudited Financial Results

SHANGHAI, June 16, 2022 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the first quart...

2022-06-16 15:58 5075

WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

PHILADELPHIA and ST. LOUIS, MO and SAN DIEGO, June 15, 2022 /PRNewswire/ -- WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based inSt. Louis and San Diego, today announced a ...

2022-06-16 08:00 2691

I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210

SHANGHAI and GAITHERSBURG, Md., June 15, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced two assets the Company has licensed from partner Morpho...

2022-06-15 22:37 3419

Burning Rock Presents Latest Clinical Data from THUNDER Study at 2022 ASCO Annual Meeting

SHANGHAI, June 15, 2022 /PRNewswire/ -- Burning Rock (NASDAQ:BNR) presented the final results from the multi-center case-control THUNDER study (THe UNintrusive Detection of EaRly-stage cancer, NCT04820868) in a poster entitled "Unintrusive multi-cancer detection by circulating cell-free DNA methy...

2022-06-15 20:01 2970

J INTS BIO, Oral presentation of Preclinical results of its Novel Oral 4th Generation EGFR TKI 'JIN-A02' at the upcoming 2022 World Conference on Lung Cancer in Vienna, Austria

SEOUL, South Korea, June 14, 2022 /PRNewswire/ -- J INTS BIO announced that it will be presenting the preclinical results of its NSCLC candidate 'JIN-A02' at the upcoming 2022 IASLC World Conference on Lung Cancer, to be held inVienna, Austria from 6th to 9th August.

2022-06-14 22:00 1485

Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences

SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, June. 14, 2022  /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of ...

2022-06-14 20:00 2103

United Imaging Shows Up Big, Differently

Focusing squarely on its Equal Healthcare for All™ mission, the company had its flagship digital PET/CT driven across the border on a trailer to SNMMI 2022. HOUSTON, June 14, 2022 /PRNewswire/ -- United Imaging, a global leader in manufacturing advanced medical imaging and radiotherapy equipment,...

2022-06-14 20:00 1987

Zhimeng Biopharma will report positive phase 1b trial results on its HBV capsid inhibitor ZM-H1505R in the upcoming International Liver Congress

SHANGHAI, June 14, 2022 /PRNewswire/ -- Shanghai Zhimeng Biopharma announces that it will report the positive results obtained from a phase1b study on its HBV capsid inhibitor ZM-H1505R in the International Liver Congress inJune 22-26, 2022 (the EASL meeting).  The recently completed phase 1b stu...

2022-06-14 20:00 1912

Telix and Invicro Advance AI Partnership

MELBOURNE, Australia and BOSTON, June 14, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it has advanced a partnership with Invicro LLC (Invicro), a global, industry-leading imaging CRO, and part of REALM IDx, Inc., to develop an artificial...

2022-06-14 19:00 2900
1 ... 220221222223224225226 ... 261